Table 3.
Distribution of treatments according to molecular diagnosis
| Molecular diagnosis | Treatment | Distribution |
|---|---|---|
| ALK+ | Alectinib | 95% |
| Crizotinib | 5% | |
| EFGR+ | Erlotinib | 3,3% |
| Gefitinib | 6,7% | |
| Afatinib | 11.7% | |
| Osimertinib | 76.3% | |
| Dacomitinib | 2% | |
| ROS1+ | Crizotinib | 95% (40%a) |
| Clinical trials | 5% | |
| Entrectinib | 0% (55%a) | |
| WT | ||
| TPS ≥50% | Pembrolizumab monotherapy | 90% |
| Cisp+pmtrx | 5% | |
| Clinical trials | 5% | |
| TPS < 50% | Cisp+pmtrx | 25% |
| Carb+paclitx+beva | 5% | |
| Cisp+pmtrx+pembrolizumab | 60% | |
| Carb+ paclitx +beva+atezolizumab | 10% | |
EGFR Epidermal growth factor receptor, ALK Anaplastic lymphoma kinase, ROS1 C-ros oncogene 1, WT Wild-type, TPS Tumour proportion score, Cisp Cisplatin, Carb Carboplatin, pmtrx Pemetrexed, paclitx Paclitaxel, beva Bevacizumab
aDistribution considered in the alternative scenario in which entrectinib is a treatment alternative in ROS1-positive patients